In addition to these genomic alterations, we also observed loss of ER expression (as measured by immunohistochemistry (IHC)) in baseline tumor samples (n = 3/19, 16%), which we refer to as “loss of ER expression” because these patients were previously diagnosed with ER + /HER2- metastatic breast cancer. The gene discussed is ESR1; the disease is neoplasm.